Drug details

Talzenna (talazoparib capsules)

type of Antineoplastics PARP Inhibitors

Talzenna (talazoparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fever,
• easy bruising,
• unusual bleeding,
• pale skin,
• shortness of breath,
• cold hands and feet,
• weight loss,
• tiredness,
• weakness,
• sore throat,
• mouth sores,
• trouble breathing
• skin sores,
• purple or red spots under your skin,
• blood in your urine or stools,
• cough, and

The following drugs are related to Talzenna, either as a replacement or used together:

• Verzenio (abemaciclib tablets)
• Akeega (niraparib and abiraterone acetate tablets)
• Piqray (alpelisib tablets)
• Arimidex (anastrozole)
• Faslodex (fulvestrant)
• Femara (letrozole)
• Herceptin (trastuzumab)
• Ibrance (palbociclib capsules for oral administration)
• Kisqali (ribociclib tablets)
• Kisqali FeMara Co-Pack (ribociclib and letrozole tablets)
• Tykerb (lapatinib)
• Nolvadex (tamoxifen citrate)
• Perjeta (pertuzumab)
• Soltamox (tamoxifen citrate)
• Tukysa (tucatinib tablets)